Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
Man Mohan MehndirattaManoj GulhaneShaik A JabeenAnna PattenAmitabh DashManoj MalhotraPublished in: Epilepsia open (2021)
These data suggest adjunctive perampanel (up to 12 mg/day) may be a suitable anti-seizure medication for patients (aged ≥ 12 years) with FS, with/without FBTCS, or GTCS in India.
Keyphrases
- phase ii
- phase iii
- open label
- clinical trial
- double blind
- placebo controlled
- phase ii study
- study protocol
- end stage renal disease
- ejection fraction
- prognostic factors
- temporal lobe epilepsy
- squamous cell carcinoma
- healthcare
- peritoneal dialysis
- patient reported outcomes
- emergency department
- radiation therapy
- patient reported
- machine learning
- adverse drug